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A B S T R A C T
Complete remission (CR) after induction therapy is the first treatment goal in acute myeloid leukemia (AML)
patients and has prognostic impact. Our purpose is to determine the correlation between the observed CR/CRi
rate after idarubicin (IDA) and cytarabine (CYT) 3+7 induction and the leukemic chemosensitivity measured
by an ex vivo test of drug activity. Bone marrow samples from adult patients with newly diagnosed AML were
included in this study. Whole bone marrow samples were incubated for 48 h in well plates containing IDA, CYT,
or their combination. Pharmacological response parameters were estimated using population pharmacodynamic
models. Patients attaining a CR/CRi with up to two induction cycles of 3+ 7 were classified as responders and
the remaining as resistant. A total of 123 patients fulfilled the inclusion criteria and were evaluable for corre-
lation analyses. The strongest clinical predictors were the area under the curve of the concentration response
curves of CYT and IDA. The overall accuracy achieved using MaxSpSe criteria to define positivity was 81%,
predicting better responder (93%) than non-responder patients (60%). The ex vivo test provides better yet similar
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information than cytogenetics, but can be provided before treatment representing a valuable in-time addition.
After validation in an external cohort, this novel ex vivo test could be useful to select AML patients for 3+7
regimen vs. alternative schedules.
1. Introduction
Several clinical and biological features, like cytogenetic and mole-
cular alterations, may predict the short- and long-term outcomes in
patients with AML treated with intensive approaches [1,2]. However,
the main prognostic factor after front-line induction treatment is the
leukemic cell sensitivity to the chemotherapy itself (i.e, to achieve or
not a first CR as well as the quality and duration of the CR) [3,4]. In
order to predict response to chemotherapy, many individualized sen-
sitivity and resistance assays have been deployed for detecting ex vivo
drug-inducible cell death. Nevertheless, as far as we know, none of
them have settled into the routine medical practice [5].
The combination of IDA and CYT (3+7 schedule) is widely used as
front-line regimen in younger AML patients, resulting in CR or CR with
incomplete recovery (CRi) rates of 70–80% after one or two cycles [6].
Among patients who do not achieve CR/CRi after induction therapy,
categorized as primary refractory or resistant disease, the prognosis is
dismal [4]. We hypothesize that a reliable and automated ex vivo drug
sensitivity test accurately predicts the antileukemic efficacy of 3+ 7
induction would be valuable to preselect this regimen as the optimal
upfront chemotherapy schedule.
We present here a non-interventional prospective study assessing a
novel and actionable native environment precision medicine (PM)
method [7] (PharmaFlow platform) that could overcome some of the
previous shortcomings of ex vivo testing. The PharmaFlow platform is a
cell-based multi-color screening flow cytometry platform that in-
corporates both automated sample preparation and automated flow
cytometry, together with proprietary analytical software and a database
that achieve rapid data acquisition, analysis, and reporting of results.
This platform has the capacity to evaluate hundreds of drug combina-
tions that form the basis of treatment protocols in AML, together with
the fact that these drug combinations are evaluated in whole bone
marrow retaining the biological system as intact as possible. The aim is
to determine the ability of the PharmaFlow PM test to predict the re-
sponse to first line induction chemotherapy with CYT and IDA (3+7)
in young AML patients.
2. Patients and methods
2.1. Patients and study design
This multicenter, non-interventional prospective cohort study was
carried out in 43 Spanish institutions of the PETHEMA group. The in-
clusion period lasted five years (2011–2016), enrolling patients aged 18
years and older with newly diagnosed AML (de novo or secondary to
myelodysplastic syndromes, or therapy-related). Patients with acute
promyelocytic leukemia and those with AML derived from a chronic
myeloid leukemia were not screened. Patients were eligible for the
current analysis if they received front-line induction therapy using IDA/
CYT (3+7). All adult patients treated with other front-line regimens
were excluded from the correlation analysis, but their AML samples
were used to build pharmacodynamics (PD) population-based models.
Diagnosis and classification of AML was made according to the WHO
(World Health Classification) criteria [8]. The study was conducted
according to the Spanish law 14/2007 of biomedical research, and was
approved by the Research Ethics Board of each participating institution.
All patients provided informed consent.
2.2. Chemotherapy regimen, drugs and evaluation
Induction therapy consisted of up to two cycles of the combination
of intravenous (IV) IDA (12mg/m2/day), from days one to three, and IV
continuous perfusion of CYT (200mg/m2/day), from days one to seven.
A second 3+ 7 induction cycle was administered in patients showing a
partial remission (PR) after the first cycle. Supportive measures were
given according to local policies of each participating institution.
Fig. 1. Sequential workflow of experimental (1) and analytical (2 & 3) methods applied in the study. Whole bone marrow samples [A] were incubated
preserving the native microenvironment with drugs and drugs mixtures. Automated flow cytometry [B] followed by dot-plots analysis [C] allowed the counting after
incubation of Live Pathologic Cells (LPC) at control wells and wells with increasing drugs concentrations. Data was uploaded into the LIMS system. Response vs drug
concentration relationships were analyzed through non-linear mixed effect population modelling [E]. Predicted pharmacodynamic profiles were integrated between
the 80% confidence interval of the individual estimate of EC50 in order to calculate the area under the curve (AUC) used as a single activity marker. Similarly, a
double integration of the two-variables interaction surface function allows the calculation of the volume under the surface (VUS) that is effected by the sign (synergy
or antagonism) of the interaction [F]. Correlation of activity markers with clinical output was analyzed by Generalized Additive Models (GAM) [G] and ROC curves
[H]. (See details on individual figures).
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Response to induction chemotherapy was assessed according to the
revised Cheson criteria [9]. Patients were considered as responders if
they achieved CR or CRi within the first two identical 3+ 7 induction
cycles. Patients dying during induction before response assessment
were considered as non-evaluable. The remaining patients were clas-
sified as resistant.
2.3. Vivia’s PharmaFlow PM test
A representative workflow of the PharmaFlow PM test is shown in
Fig. 1, collecting the experimental and analytical methods applied in
this study.
2.3.1. Native environment whole bone marrow sample
Ex vivo drug sensitivity analysis was made using the PharmaFlow
platform (previously termed ExviTech®) [7] maintaining the bone
marrow (BM) microenvironment. A minimum BM sample volume be-
tween one and two ml was collected by aspiration at AML diagnosis,
before starting induction chemotherapy, and was processed by an au-
tomated method in Vivia Biotech laboratories 24 h after extraction.
Samples were incubated with CYT, IDA and/or CYT+ IDA for 48 h. A
more detailed description of the procedure has been published else-
where [7].
2.3.2. Modeling of ex vivo activity of CYT, IDA, and their combination
Evaluation of drug response was done by counting the number of
live pathological cells (LPC) remaining after incubation at increasing
drug concentrations [10]. Dying cells (apoptosis) were excluded using
Annexin V-FITC. Pharmacological responses were analyzed using PD
population-based models [10] which essentially perform the fitting of
the dependent variable (natural log of LPC) in a non-linear mixed-ef-
fects model to derive typical population values (fixed effects) and the
magnitude of inter-patient and residual variability (random effects).
Model development was performed with the first-order conditional
estimation method using interaction option with the software
NONMEM (v7.2) [11], according to the following equation:
Where LPC0 parameter refers to the number of LPC after incubation
in the absence of drug, Emax represents the maximum fractional de-
crease in LPC that the drug can elicit, EC50, is the drug concentration
exerting half of Emax, and γ is the parameter governing the steepness of
the LPC vs drug concentration (C) curve. For interaction analysis a
Surface Interaction model [12] was used to estimate the degree of sy-
nergy, referred as α parameter, between both drugs.
Interpatient variability (IPV) associated to all parameters was de-
scribed by means of an exponential model of the components of var-
iance. An additive error structure was used for the residual variability.
Population PD models were built with BM samples from 473 patients
that were incubated with CYT, 456 with IDA and 443 with CYT+ IDA.
Bayesian estimation methods were then used to retrieve individual
patient parameters based on their available exposure-response mea-
surements in conjunction with the PD population parameters.
Evaluation of the population PD models was done by the simulation-
based procedure visual predictive check [13]. Five hundred experi-
mental scenarios equal to the original ones were simulated using the
selected models and the corresponding parameters. In each simulated
set and for each concentration lever the 2.5, 50, and 97.5th percentiles
of the LPC distribution were calculated, then the 95% confidence in-
tervals for the above mentioned percentiles were computed and re-
presented graphically together with the 2.5, 50, and 97.5th percentiles
obtained from the raw data.
2.3.3. Probability of clinical outcome modeling clinical correlation
Individual response profiles normalized with respect to LPC0, were
integrated between the concentration points corresponding to the 20th
and 80th percentiles of the distribution of estimated individual EC50
values, to obtain the values of the areas under the curves (AUCs) that
were used as a descriptor of the ex vivo drug effect (i.e., the higher the
AUC, the lower the cytotoxic effect (efficacy or potency) of the drug.
The individual AUC values were correlated to the actual patient´s
response after induction therapy (non-responder [PR or resistant dis-
ease] vs. responder [CR or CRi]). The probability of being non-re-
sponder was modeled using binary logistic generalized additive models
(GAM) based on the binomial distribution that included either one bi-
or two univariate smooth functions of the AUCs of CYT and IDA.
Additionally, univariate smooth functions of the LPC0, α, and the pre-
post incubation difference of the percentage of LPC in control wells (to
detect for any possible effect of spontaneous cell death) were included
as well, but discarded afterwards because they were not related to the
clinical response. Also, the predictive ability of relevant patients’
characteristics (age and sex, presenting leukocyte count, performance
status, mutations in the NPM1 or FLT3 genes, and cytogenetic risk
group) on top of pharmacodynamics data was explored by introducing
them as parametric model terms in auxiliary GAMs. P-spline bases were
used as smoothers for univariate smooth functions; tensor products of
univariate P-spline smooths were used for constructing bi-variate
smooth functions. All smoothing bases had dimension three.
Table 1
Patients’ characteristics and clinical response of the 123 patients incubated with
CYT and IDA.







Median (range) 49 (19-71) 55 (22-67) 0.224 a
18–29 [n (%)] 8 (8.7) 2 (6.5) 0.758 b
30–39 [n (%)] 17 (18.5) 5 (16.1)
40–49 [n (%)] 23 (25.0) 5 (16.1)
50–59 [n (%)] 22 (23.9) 10 (32.3)
>60 22 (23.9) 9 (29.0)
Gender
Male [n (%)] 42 (45.7) 16 (51.6) 0.565 b
Female [n (%)] 50 (54.3) 15 (48.4)
ECOG
0–1 [n (%)] 69 (87.3) 27 (100.0) 0.062 c
2–4 [n (%)] 10 (12.7) 0 (0.0)
FAB subtype
M0 [n (%)] 3 (3.6) 5 (17.9) 0.166 b
M1 [n (%)] 19 (22.6) 4 (14.3)
M2 [n (%)] 23 (27.4) 9 (32.1)
M4 [n (%)] 22 (26.2) 5 (17.9)
M5 [n (%)] 16 (19.0) 5 (17.9)
M6 [n (%)] 1 (1.2) 0 (0.0)
WBC (count × 109L−1)
Median (range) 22.1 (0-288.4) 22.3 (1-157) 0.461 a
0–10 [n (%)] 31 (33.7) 12 (38.7) 0.528 b
10–50 [n (%)] 37 (40.2) 14 (45.2)
>50 [n (%)] 24 (26.1) 5 (16.1)
Cytogenetic risk profile
Favorable [n (%)] 11 (13.1) 0 (0.0) < 0.001 b
Intermediate [n (%)] 68 (81.0) 11 (40.7)
Adverse [n (%)] 5 (6.0) 16 (59.3)
FLT3-ITD status
Wild type [n (%)] 72 (79.1) 28 (90.3) 0.161 b
Mutant [n (%)] 19 (20.9) 3 (9.7)
NPM1 status
Wild type [n (%)] 47 (57.3) 22 (78.6) 0.045 b
Mutant [n (%)] 35 (42.7) 6 (21.4)
Patients with missing data have not been included in the denominators of the
relative frequencies.
a Mann-Whitney test.
b Pearson’s chi-square test.
c Fisher’s exact test.
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Coefficients of the smooth functions were estimated using penalized
iteratively re-weighted least squares. Minima of the scaled Akaike in-
formation criteria were used to find the optimal values of the smoothing
parameters.
2.4. Data collection and study endpoints
Demographic data (gender, age) were prospectively collected since
diagnosis, as well as the following parameters: WBC in PB, ECOG per-
formance status, type of AML (FAB classification, de novo vs. secondary
AML), karyotype [14], FLT3 and NPM1 mutation status, hematological
Fig. 2. Visual predictive check of the population pharmacokinetic models of cytarabine and idarubicin. Open circles are the observed data points, the solid
and dashed red lines are, respectively, the median and the 5-95th percentiles of the observed distribution of ln(cells), and the semitransparent red and blue bands
represent, respectively, the simulation-based 95% confidence intervals for the median and 5-95th percentiles of the estimated population distribution of ln(cells).
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response, number of 3+7 induction cycles, date of response, date of
last follow-up, and post-remission therapy. All data collection forms
and clinical records were monitored.
The primary end-point was evaluate the predictive capacity of the
ex vivo results. First, the CR/CRi rate observed in patients treated with
up to two induction cycles of 3+ 7 was recorded and monitored. This
was correlated with the ex vivo drug sensitivity analyses performed in
the same cohort of patients. As a secondary end-point, the overall
survival (OS) probability was also calculated according to the observed
and predicted response after induction.
Since the prediction of outcome to front-line induction therapy is
likely to be most beneficial to elderly patients, we performed sensitivity
analyses of the clinical correlation by re-running the GAMs within the
cohort aged 60 years or more (n=31).
2.5. Statistical analyses
The probability of response modeling was performed with the mgcv
package (v1.8–23) run in the R environment (v3.4.3) for statistical
computing [15]. The empirical ROC curves were calculated for the
probabilities of being non-responder from each GAM. The AUCs of ROC
curves were computed using the trapezoidal rule. In addition, three cut-
points to define positivity and derive classification probabilities (sen-
sitivity and specificity) were established for each ROC curve. One used
a geometric criterion, by selecting the closest point to the (1,0) co-
ordinate (left upper corner of the [sensitivity,1−specificity] plane),
another was set by maximizing both sensitivity and specificity
(MaxSpSe) and the other by minimizing a misclassification cost term
(mMCT) [16], assigning a greater cost to false positives than to false
negatives (prioritizing specificity over sensitivity).
The OS was described with the Kaplan-Meier method and compared
between the patients predicted to be non-responder and responder as




Overall, 954 BM samples from patients with AML suspicion were
received at the laboratory. Of them, 316 (33%) were not evaluable
because of the following laboratory technical issues: 1) low sample
cellularity (187 patients), 2) low cell viability (below 60%) in control
wells after incubation (67), 3) insufficient sample volume (< 500 μL)
(38), and 4) other reasons such as clotted sample (24). Other 26 pa-
tients (3%) did not fulfill the diagnosis criteria. Among the 612 ana-
lyzed samples, 139 where used only for assay adjustment and did not
contain necessary data for the final model. Overall, 473 patients sam-
ples (50%) were used to build the PD models, and a complete data set
was monitored in 237 of them (50%). Among the monitored patients,
114 were not evaluable for the correlation analyses due to: 1) induction
death (20 patients), 2) not first line of treatment (11), and 3) other
induction schedule (83). Finally, 123 monitored patients (52%) fulfilled
the inclusion criteria defined in the study and were evaluable for the
correlation analyses (see CONSORT diagram in supplementary Fig. 1).
The main patient and disease characteristics of these 123 patients re-
garding the clinical response are displayed in Table 1. In summary,
median age was 50 years (range, 19 to 71), 109 patients (89%) were
diagnosed with de novo AML, and 21 patients (17%) were categorized
as having high-risk cytogenetics. Only the cytogenetic risk group and,
marginally, the presence of mutations in the NPM1 gene were sig-
nificantly associated with clinical response to induction and the result
of the PM test. Post-remission therapy consisted of allogeneic stem cell
transplant (SCT) in 33 patients (27%), and chemotherapy with or
without autologous SCT in 66 patients (54%).
3.2. Ex vivo PharmaFlow test characterization of CYT-IDA combination
Visual predictive checks graphs were generated for the single drugs
PD models (Fig. 2). Most of the observations were contained within the
simulation-based 95% confidence intervals of the 2.5–97.5 th popula-
tion percentiles proving good predictability of the selected models.
Pharmacodynamic population parameters as well as variability and
error values are shown in Table 2. The typical parameter values for
Table 2
Estimation of the ex vivo population pharmacodynamic parameters.
Parameters typical and random (variability and residual error percentage)
are shown together with the corresponding relative standard error calculated
as the ratio between the standard error provided by NONMEM and the es-
timate. Estimates of inter-patient variability (IPV) are expressed as coeffi-
cient of variation (%).
Single Drugs
Parameter (units) Cytarabine Idarubicin
LPC0 (cells) 7530 (4.2) 7270 (4.8)
EMAX (unitless) 1 (-) 1 (-)
EC50 (μM) 6.94 (13.3) 0.087 (9·2)
γ(unitless) 0.684 (-) 1.14 (-)
Residual Error (log(μM)) 0.231 (2.9) 0.237 (3.2)
Inter-patient variability (IPV)
LPC0 89.7 (2.4) 92.7 (2.6)
EMAX N/D N/D
EC50 229 (4.4) 159 (4.5)
γ N/D N/D
Residual Error 50.5 (3.8) 45.8 (4)
Drug Combination
Parameter (units) Cytarabine+ Idarubicin
α (unitless) 1.1 (13)
IPV α [CV(%)] 176 (4·8)
Residual Error [log(μM)] 0.299 (4.2)
IPV Residual Error 58.3 (4.4)
Fig. 3. Regression hyperplane of the predicted probability of resistance
over the AUCs of cytarabine and idarubicin. The AUCs are a summary of
pharmacodynamic parameters such that the higher the AUC the lower the cy-
totoxic effect (efficacy or potency) of the drug. The regression hyperplane has
been obtained using bi-dimensional smooth functions in a binary logistic GAM.
AUC: area under the curve, GAM: generalized additive model.
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maximal fractional effect (Emax) were set to 1 for both drugs, and was
limited to the range 0-3. The typical value for the alpha parameter of
the interaction model was 1.1 (Table 2), indicating slight synergistic
interaction between IDA and CYT in the ex vivo combination experi-
ments.
3.3. Clinical responses among AML patients treated with CYT-IDA
CR/CRi was achieved after one (88, 96%) or two (4, 4%) identical
induction cycles in 92 out of 123 patients (75%) included in the cor-
relation study.
3.4. Correlation between ex vivo activity and clinical response to CYT-IDA
Fig. 3 depicts the predicted surface fitted by the GAM representing
the probability of being non-responder for the observed range of the
individual AUC values. The model presented used a bivariate smooth
function of CYT and IDA; the models that used univariate smooths (see
Supplementary Fig. 2) achieved worse fit. Higher CYT and IDA AUC
values were associated with greater probability of being non-responder,
albeit the relationship was non-monotonical. Sensitivity/specificity
values ranged from 81% / 82%, to 61% / 95%, based on the cut-point
selected (Fig. 4A). The positive/negative predictive values (PPV/NPV)
ranged from 60% / 93% to 79% / 88%. Fig. 4B shows the confusion
matrix obtained using the MaxSpSe cutoff point.
In the auxiliary models, only the cytogenetic risk group provided
independent additional predictive information on top of CYT and IDA
pharmacodynamics, the latter remaining significantly associated with
response no matter of patients’ clinical characteristics. A simple logistic
model of the probability of being non-responder over the cytogenetic
risk group (favorable/intermediate/adverse) explained less variability
(29.4%) than the GAM over the AUC values (40.8% in the subset of 111
patients in whom the cytogenetic risk was informed) (Fig. 6). Fur-
thermore, the model with the pharmacodynamics data explained sig-
nificantly more variability than the cytogenetic information alone
(p= 0.001, details available or request).
The sensitivity analyses showed that the predictive ability of the PM
test remained intact within the cohort aged ≥60 years (Supplemental
Fig. 3), although in this case most of the discriminative information was
provided by CYT data; IDA AUC values were in general higher in older
patients.
3.5. OS according to the ex vivo activity and observed clinical response
The OS was significantly shorter in patients predicted to be non-
responders than in patients predicted to be responders regardless of the
cut-point used to classify them. The median OS among patients pre-
dicted to be non-responders ranged from 344 to 589 days (Fig. 5). It
was not reached in patients predicted to be responders. The hazard
ratios (HR) of death (patients predicted to be non-responders vs. re-
sponders) ranged from 2.46 (1.38–4.36) to 3.44 (1.88–6.28). The values
for the groups defined by actual clinical response were similar (median
OS among non-responders: 279 days; HR [resistant vs. CR/CRi]: 3.17).
4. Discussion
This study shows good correlation between the hematological re-
sponse to IDA/CYT 3+7 induction and the observed leukemic che-
mosensitivity measured by a novel approach to ex vivo testing of drug
activity. The statistical model that was built using the PharmaFlow PM
test showed a good correlation (81%) with hematological responses
observed in patients. A 93% of patients predicted sensitive indeed
Fig. 4. Empirical and smoothed (binormal) ROC curves of the probability of resistance obtained in the binary logistic GAM. A. - Open circles are the pairs of
sensitivity and 1−specificity values at the estimated discrete individual values of the probability of resistance (used as a marker to classify the patients as responder
or resistant), the solid large circles represent the pairs of sensitivity and 1−specificity values at the selected cut-points that were obtained with each of the three
criteria specified in the text: ‘MaxSpSe’ selects the point that maximizes both, the sensitivity and the specificity; ‘Geometric’ selects the closest point to the (1,0)
coordinate (left upper corner of the [sensitivity,1−specificity] plane); and ‘mMCT’ selects the point that minimizes a misclassification cost term that assigned a
greater cost to false positives than to false negatives (prioritizes specificity over sensitivity).
AUC: area under the curve, CI: confidence interval, FPF: false positive fraction, NPV: negative predictive value, PPV: positive predictive value, Se: sensitivity, Sp:
specificity, TPF: true positive fraction.
B.- Confusion matrix for MaxSpSe cutoff.
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achieved CR/CRi, potentially allowing for better selection of the front-
line chemotherapy schedule. However, a validation study in an external
cohort must be performed before using the PharmaFlow PM test in the
upfront clinical setting.
Several studies have analyzed the correlation between ex vivo drug
testing and clinical outcomes in adult AML patients by different
methods [17–23], but none was adopted in the routine clinical practice.
Our novel approach was designed to overcome some of the ex vivo
testing limitations of the last 30 years. Thus, the PharmaFlow PM test
has several relevant aspects differing from previously reported assays:
1) contrarily to others using ficol isolated leukemic cells, we used whole
BM samples diluted to keep, at least in part, the native environment. We
have shown this prevents major artifacts on drug activity [7]. As the
tumor microenvironment has been implicated in the drug-resistance
mechanisms [24–27], we can hypothesize that using whole BM samples
could lead to more reliable results; 2) we employed PD models to
analyze the data albeit the correlations were performed in relatively
small number of patients. This method increases accuracy by fitting
dose-response population data in one single step [28]; and 3) we used a
proprietary automated flow cytometry platform (PharmaFlow) that
could lower experimental errors, providing accurate data from patient
samples.
Our study methodology has several limitations that deserve some
comments: 1) the study was designed to create a predictive model for
the clinical response in terms of CR/CRi vs. PR/resistance, using the
classical criteria, whilst no systematic/centralized minimal residual
disease assessment was performed. We can speculate that a more pre-
cise response assessment by flow cytometry could improve the accuracy
of our observations; 2) the PharmaFlow PM test analyzed the main
baseline leukemic population, not facing up the presence of phenoty-
pically different subclones before and after induction; 3) the test was
not predicting the actual overall response (it was not aimed to predict
induction death); 4) the test was not evaluable in a sizable proportion of
patients mainly due to low cellularity or low viability samples; 5) al-
though the incubation time was relatively short, additional transpor-
tation and processing time could lead, in some patients, to a non-af-
fordable delay to start induction chemotherapy while receiving the test
report; and 6) our results are not yet validated in an independent co-
hort. Finally, we should speculate about some potential causes about
why the PharmaFlow could not predict some selected cases: 1) the test
analyzed the main leukemic population, not facing up the presence or
marginal resistant subclones, 2) the test was not reproducing the leu-
kemic stem-cell niche who could have an in vivo protective effect
against chemotherapy agents, 3) the test was not taking into account
some pharmacodynamic and pharmacokinetic parameters which may
influence the actual response to chemotherapy (e.g., drug-drug inter-
actions during induction, pharmacogenetic polymorphisms); and 4)
technical issues/limitations of the test.
To identify the ex vivo variables associated to hematological re-
sponse, sophisticated regression analyses were performed. The AUC of
the concentration-response curves yielded a useful summary of the
pharmacodynamic parameters for the purposes of predicting the clin-
ical response. Both drugs provided meaningful and independent in-
formation, as can be observed in predicted surface of being non-re-
sponder shown in Fig. 3; When IDA is inactive at maximal IDA AUC, the
AUC of CYT leads the prediction with a classical dose-response curve
(red). Conversely, When CYT is inactive IDA leads the prediction with a
classical dose response curve (blue). When one of the drugs is very
active (low AUC) the other shows a more limited effect, still consistent
with higher AUC corresponding to higher probability of resistance. This
behavior is coherent and consistent with the expectations; higher AUC
of either drug, i.e. lower activity, implies higher probability of re-
sistance.
Notably, the observed interaction between both drugs was not
highly synergistic, and did not independently correlate with hemato-
logical response. Contrarily to other reports [29], our data suggest that
the effectiveness of the CYT-IDA combination may rely in their com-
plementary activities, and marginally on their synergism.
Diagnostic accuracy of a predictive test is usually assessed by the
Fig. 5. Kaplan-Meier plots of overall survival. The three panels deptict the
pairs of survival functions for patients classified as responder (solid black lines)
and resistant (solid red lines) according to the cut-points of the estimated
probability of resistance that were obtained with each of the three criteria
specified in the text (panel A: ‘MaxSpSe’, panel B: ‘Geometric’, and panel C:
‘mMCT’). The dashed lines represent the survival functions of clinical re-
sponders (black lines) and resistant patients (red lines). The hazard ratios of
death were obtained from a Cox regression model that used the patients who
were predicted to be responder as the reference category (patients predicted to
be resistant over patients predicted to be responder).
CI: confidence interval, HR: hazard ratio
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maximum sensitivity and specificity values achieved in ROC curves
(Fig. 4A, “maxSpSe”). However, we considered an alternative approach
to maximize the ability to identify patients as non-responder (i.e, PPV)
or responder (i.e, NPV), while prioritizing specificity over sensitivity
(“mMCT”) to account for the high clinical cost of false positives (de-
nying potentially effective 3+ 7 schedule). Although the geometric
cutoff point balanced both aspects, the final selected cutoff point in
ROC curve was the MaxSpSe to construct the confusion matrix and
derive classification probabilities, achieving high values for both spe-
cificity and sensitivity, as well as good PPV and NPV (Fig. 4B). The
accuracy achieved by the PharmaFlow PM test using the aforemen-
tioned MaxSpSe criteria to define positivity was 81%, predicting better
responder (93%, NPV) than non-responder patients (60%, PPV). We can
speculate that, in order to improve first CR/CRi rates, patients predicted
as non-responder to CYT-IDA could be proposed for alternative induc-
tion schedules or front-line clinical trials.
The estimated OS was significantly better in patients predicted to be
responder. This is not surprising, because PharmaFlow PM test accu-
rately predicted the response, and achieving a first CR leads to im-
proved OS after 1st line in AML [30]. Interestingly, the OS probability
was similarly discriminated by the test result (responder vs. non-re-
sponder) compared with the actual clinical response (CR/CRi vs. re-
sistance).
The information about the cytogenetic risk was less predictive than
the pharmacologic parameters; Deviance explained 29.4% for cytoge-
netics, and 40.8% for PM test. Nonetheless, cytogenetics still proved to
be of prognostic relevance in these patients. Fig. 6 compares clinical
correlation of cytogenetics vs PM Test, on a cohort of 111 patients
sharing both results. In both approaches prediction of sensitive patients
is better than resistant patients (NPV vs PPV). While PM Test has better
prediction of sensitive patients (NPV=93% vs 88%), cytogenetics
shows a 20% improvement in the prediction of resistant patients.
However, results from cytogenetic risk are available typically in 10–14
days and thus after patient treatment, while results from this novel ex
vivo PM Test are available in 48–72 h prior to patient treatment. It
should be noted that the model showed an acceptable performance
among patients older than 60 years old (which are at higher risk of
treatment related death), and retained its independent predictive value
among the adverse cytogenetic subgroup of patients (which are fre-
quently offered non-intensive options because of high resistance rate).
We can hypothesize that the PM test could be valuable for selecting
candidates to IDA and CYT 3+7 among these critical subsets.
In conclusion, our novel approach to ex vivo testing using the
PharmaFlow PM platform provided drug sensitivity parameters that
were integrated in a flexible generalized additive logistic regression
model with an outstanding predictive accuracy for hematological
Fig. 6. Comparison between clinical correlation of cytogenetics (left) and PM Test (right), on a cohort of 111 patients sharing both results. ROC curves (top)
and confusion matrices for MaxSpSe cutoff (down). Deviance explained is 29.4% for cytogenetics, and 40.9% for PM test.
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response after front-line induction with CYT-IDA 3+7. After validation
in an external cohort, our diagnostic tool could be useful to select AML
patients for 3+7 regimen vs. alternative schedules. The PETHEMA
AML group is launching a clinical trial to confirm the predictive value
of this new PM Test.
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